FDA rejects Novocure's Optune Mya for lung cancer brain metastases; Synchron pauses Stentrode enrollment; MRI model predicts meningioma grade

An operating microscope on a wheeled stand with an articulated boom arm, its binocular head angled down over an empty table.

The Food and Drug Administration (FDA) issued a not-approvable letter for Novocure's Optune Mya device in brain metastases from non-small cell lung cancer, citing uncertainty about clinical benefit, the company said Nov. 9.

Synchron paused enrollment in its Stentrode brain-computer interface trials over a lead problem, a machine learning model predicted meningioma grade from preoperative MRI, and a meta-analysis tied supratotal resection to longer survival in IDH-mutant grade 2 gliomas.

  • FDA Nov 9, 2026
    Novocure said Nov. 9 that the Food and Drug Administration (FDA) issued a not-approvable letter for Optune Mya, which uses low-energy electrical fields and is intended to treat non-small cell lung cancer that has spread to the brain, citing uncertainty around the degree of clinical benefit, MedTech Dive reported. The pivotal trial showed delayed brain metastasis progression compared with best supportive care but no difference in secondary end points, including neurocognitive failure and overall survival. The FDA raised no safety concerns, and Novocure intends to meet with the FDA about other options, the company said.
    Source: MedTech Dive
  • Technology Nov 12, 2026
    Synchron has voluntarily paused enrollment in trials of its second-generation Stentrode brain-computer interface because of a performance problem with the lead connecting the endovascular electrode array to the implanted electronics, WIRED reported Nov. 12, according to Implantable Device. The company said it had identified no associated safety issues, and the pause was not FDA-directed. The available reports did not establish the failure mechanism or its frequency, according to Implantable Device.
  • AI Nov 13, 2026
    A retrospective diagnostic study published online in the Journal of Neurosurgery on Nov. 13 built a machine learning model to predict binarized World Health Organization grade (1 versus 2 or 3) in the BraTS Meningioma Challenge cohort, using 909 patients from six academic medical centers for training and internal validation and 210 for a one-time final external validation. The model achieved an area under the receiver operating characteristic curve of 0.824 (95% CI 0.755 to 0.883) on unseen test data. The authors said the externally validated model accurately predicted meningioma grade using routine preoperative MRI.
  • Research Nov 12, 2026
    An individual patient data meta-analysis of 876 patients with IDH-mutant World Health Organization (WHO) grade 2 and 3 gliomas, published online in Neurosurgery on Nov. 12, used reconstructed patient data from studies from 2010 to 2025. In WHO grade 2 gliomas, 16-year overall survival was 96.3% after supratotal resection versus 66.8% after total resection (P < .001). Grade 2 astrocytomas showed a restricted mean survival time gain of 32.6 months, while the 7.0-month difference in oligodendrogliomas was not significant (P = .078).

The weekly innovation roundup for neurosurgery, published every Sunday for the week before; every item links to its sources. Latest neurosurgery news · All specialties

Latest news

Tagged neurosurgery, from the daily briefing

  1. Synchron pauses trials of its wireless brain implant and cuts jobs, saying the pause is not safety related
  2. Brain implants let people with ALS speak and sing, The New York Times reports
  3. FDA clears AI that flags brain aneurysms larger than 3 mm on head CT angiography and tracks their growth between scans

See all the latest news